Our current findings significantly expand the potential patient population, suggesting that diagnosis and subsequent therapeutic inhibition of ADAM8-positive tumors may have much broader implications for breast cancer patients than originally anticipated. This evidence concerns the gene ADAM8 and breast cancer.